How it may work
Investigational agonism of GLP-1, GIP and glucagon receptors.
Guide-level evidence orientationEvidence level B
Level B describes a substantial but bounded human evidence base for this exact question; read the conclusion for whether the result is positive, null or bounded.
This guide-level grade is an orientation, not a direction-of-effect label, product grade, claim or personal recommendation.Why people are interested
A triple-receptor medicine candidate being studied for metabolic disease and weight management. It remains a controlled clinical research programme.
Library trackMedical research
Last reviewed20 Aug 2026
Guide scopeIngredient research only
What people have studied
Late-stage obesity research shows substantial weight-loss effects, but it remains a medical development programme rather than a longevity supplement.
What to consider
Requires regulated medical development and monitoring; counterfeit supply is a serious risk.
Local pathway
Investigational only; not an approved prescription product or public-use option. Not sold by CELLIVITY.
Sources + indexes
See where the explanation comes from.
Open the linked research and official records behind this guide. Early topics may begin with a research index while stronger sources are added.